PositiveID (PSID) Successfully Completes Phase II of Its GlucoChip Glucose-Sensing Microchip for Patients With Diabetes

DELRAY BEACH, Fla., Aug. 17, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today it has successfully completed Phase II testing of its GlucoChip™ glucose-sensing microchip for patients with diabetes. In Phase II, the Company, in conjunction with its development partner RECEPTORS LLC ("Receptors"), created and demonstrated a stable and reproducible, closed-cycle continuous glucose-sensing system that consistently functions in the human blood fractions that are relevant to glucose analysis in the human body. The companies have published results from their laboratory testing in a white paper titled, "Development of the Sensing System for an Implantable Glucose Sensor," available at http://www.positiveidcorp.com/files/ImplantableGlucoseSensorWhitePaper.pdf.